Logo

MDCX

Medicus Pharma Ltd. Common Stock

MDCX

Medicus Pharma Ltd. Common Stock • NASDAQ
$2.20 ▲ 7.32% (+0.15)
Market Cap $48.46 M
52w High $8.94
52w Low $1.79
Dividend Yield 0%
P/E -0.99
Volume 134.73K
Outstanding Shares 22.03M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $6.709M ▲ $-15.981M ▼ 0% $-1.12 ▼ $-15.981M ▼
Q2-2025 $0 $6.016M ▲ $-6.176M ▼ 0% $-0.43 ▼ $-6.016M ▼
Q1-2025 $0 $5.126M ▲ $-5.102M ▼ 0% $-0.42 ▼ $-5.102M ▼
Q4-2024 $0 $2.351M ▼ $-2.275M ▲ 0% $-0.239 ▲ $-1.478M ▲
Q3-2024 $0 $2.979M $-2.959M 0% $-0.31 $-2.924M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $8.662M ▼ $9.978M ▼ $10.783M ▲ $-910.126K ▼
Q2-2025 $9.67M ▲ $11.935M ▲ $8.686M ▲ $3.249M ▲
Q1-2025 $3.982M ▼ $5.658M ▲ $3.51M ▲ $2.148M ▼
Q4-2024 $4.164M ▼ $5.647M ▼ $2.512M ▲ $3.135M ▼
Q3-2024 $5.306M $5.721M $2.229M $3.492M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-15.981M ▼ $-6.832M ▼ $-4.689M ▼ $10.484M ▼ $-1.007M ▼ $-6.832M ▼
Q2-2025 $-6.176M ▼ $-5.469M ▼ $0 $11.156M ▲ $5.687M ▲ $-5.469M ▼
Q1-2025 $-5.102M ▼ $-3.941M ▼ $0 $3.759M ▲ $-181.893K ▲ $-3.941M ▼
Q4-2024 $-2.275M ▲ $-3.045M ▲ $0 $1.868M ▲ $-1.142M ▲ $-3.045M ▲
Q3-2024 $-2.959M $-3.068M $0 $-35.04K $-3.103M $-3.068M

Five-Year Company Overview

Income Statement

Income Statement Medicus Pharma is still a pure development-stage biotech. It has essentially no revenue and only small operating losses so far, which is normal for a company at this stage. The income statement is driven almost entirely by research, development, and corporate costs, with no commercial products yet to offset them. Losses have been persistent, and earnings per share are negative, reflecting the early, pre-revenue nature of the business rather than any sign of mature profitability.

Balance Sheet

Balance Sheet The balance sheet is very light, with minimal assets and no meaningful cash buffer shown in the recent history. There is no recorded financial debt, which reduces leverage risk but also suggests the company has relied mainly on equity and small-scale funding. Historical negative equity signals that accumulated losses have, at times, exceeded the book value of the company. Overall, the balance sheet looks thin and emphasizes how dependent the business is on fresh capital as it advances its pipeline.

Cash Flow

Cash Flow Cash flow is modestly negative, entirely driven by spending on operations such as trials and corporate overhead, with no inflows from product sales. There is effectively no capital expenditure base yet, which is consistent with an asset-light, R&D-focused biotech model. The pattern signals that Medicus will likely need ongoing external financing to support clinical development and reach any commercial stage. The main risk here is funding continuity rather than heavy spending on fixed assets.

Competitive Edge

Competitive Edge Medicus operates in highly competitive oncology and dermatology markets but is focused on specific, underserved niches. Its dissolvable microneedle patch for skin cancer aims to offer a non-surgical, cosmetic-friendly alternative to existing treatments, which could be compelling if late-stage data hold up. Teverelix targets advanced prostate cancer patients with high cardiovascular risk, where existing therapies have safety limitations, giving it a clear differentiation angle. The company’s patents around the microneedle platform and its late-stage prostate cancer asset provide an emerging moat, but everything still depends on clinical outcomes, regulatory feedback, and eventual physician adoption in crowded therapeutic areas.

Innovation and R&D

Innovation and R&D Innovation is the core of the Medicus story. The microneedle patch for basal cell carcinoma uses targeted, localized chemotherapy through a dissolvable patch instead of surgery, addressing pain, scarring, and convenience issues. Teverelix, acquired through Antev, is designed as a next-generation hormone therapy with a potentially better cardiovascular profile and a convenient dosing schedule, and is also being explored in a novel urology indication. The company is positioning its microneedle platform for broader use in other skin diseases and is exploring collaborations in areas like mRNA delivery. Overall, R&D is focused, differentiated, and built around platform technologies that could be extended if early programs succeed, but they remain clinically and regulatorily unproven.

Summary

Medicus Pharma is a very early, clinical-stage biotech with no revenue, small but consistent losses, and a very lean balance sheet, making it highly dependent on future financings. The investment case revolves around two main assets: a non-invasive microneedle patch for common skin cancer and a hormone-based therapy for advanced prostate cancer, both targeting clear unmet needs and backed by intellectual property. If trials continue to show strong results and regulators are supportive, these programs could unlock meaningful commercial potential, and the microneedle platform might be extended to other conditions. At the same time, the company carries the typical risks of small biotechs: clinical trial uncertainty, regulatory hurdles, funding needs, and the challenge of breaking into markets dominated by established treatments and large pharmaceutical players.

NEWS

November 24, 2025 · 8:00 AM UTC

Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers

Read more

November 17, 2025 · 7:30 AM UTC

Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Read more

November 17, 2025 · 7:30 AM UTC

Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Read more

November 14, 2025 · 5:00 PM UTC

Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights

Read more

November 13, 2025 · 7:30 AM UTC

Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Read more